diflunisal has been researched along with Disease Exacerbation in 5 studies
Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.
diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rubin, J | 1 |
| Maurer, MS | 1 |
| Magrinelli, F | 1 |
| Fabrizi, GM | 1 |
| Santoro, L | 1 |
| Manganelli, F | 1 |
| Zanette, G | 1 |
| Cavallaro, T | 1 |
| Tamburin, S | 1 |
| Adams, D | 2 |
| Cauquil, C | 2 |
| Théaudin, M | 2 |
| Berk, JL | 1 |
| Suhr, OB | 1 |
| Obici, L | 1 |
| Sekijima, Y | 1 |
| Zeldenrust, SR | 1 |
| Yamashita, T | 1 |
| Heneghan, MA | 1 |
| Gorevic, PD | 1 |
| Litchy, WJ | 1 |
| Wiesman, JF | 1 |
| Nordh, E | 1 |
| Corato, M | 1 |
| Lozza, A | 1 |
| Cortese, A | 1 |
| Robinson-Papp, J | 1 |
| Colton, T | 1 |
| Rybin, DV | 1 |
| Bisbee, AB | 1 |
| Ando, Y | 1 |
| Ikeda, S | 1 |
| Seldin, DC | 1 |
| Merlini, G | 1 |
| Skinner, M | 1 |
| Kelly, JW | 1 |
| Dyck, PJ | 1 |
| Labeyrie, C | 1 |
| Beaudonnet, G | 1 |
| Algalarrondo, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis[NCT06034405] | 1,663 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| The Effect of Diflunisal on Familial Amyloidosis[NCT00294671] | Phase 2/Phase 3 | 130 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline of the Kumamoto Score (0-102 points, increasing with disease severity), a clinical neurologic scale of motor, sensory, and autonomic function combined with heart and kidney end organ measures developed to track disease progression in Familial Amyloid Polyneuropathy (ATTR-FAP) (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | 3.1 | 1.9 |
| Placebo | 8.0 | 4.1 |
The product of body mass index (BMI) and serum albumin level (g/L) [kg/M2xg/L]. (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | kg/M2xg/L (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | -33.7 | -18.7 |
| Placebo | -67.9 | -38.5 |
The primary endpoint, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurologic deficits) to 270 points (no detectable peripheral nerve function). (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | 8.2 | 6.2 |
| Placebo | 26.3 | 12.5 |
The 36 item short-form health survey (SF-36) was used to assess the difference between treatment groups for change of mental component scores over 2 years treatment. Range 0-100; lower scores reflect lower quality-of-life. (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | 3.5 | 2.5 |
| Placebo | -0.9 | 0.8 |
The 36 item short-form health survey (SF-36) was used to assess the difference between treatment groups for change of physical component scores over 2 years treatment. Range 0-100; lower scores reflect lower quality-of-life. (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | 1.2 | 0.7 |
| Placebo | -4.9 | -1.9 |
4 reviews available for diflunisal and Disease Exacerbation
| Article | Year |
|---|---|
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Topics: Amyloid Neuropathies, Familial; Amyloidosis; Arrhythmias, Cardiac; Benzoates; Benzoxazoles; Biopsy; | 2020 |
Pharmacological treatment for familial amyloid polyneuropathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Disease Progression; Humans; Oligonucleoti | 2020 |
[Familial amyloid polyneuropathies: therapeutic issues].
Topics: Amyloid Neuropathies, Familial; Antibodies, Monoclonal; Benzoxazoles; Clinical Trials as Topic; Difl | 2012 |
TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Clinical Trials, Phase III as Topic; Diflunisal; Disea | 2016 |
1 trial available for diflunisal and Disease Exacerbation
| Article | Year |
|---|---|
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.
Topics: Aged; Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Difl | 2013 |